[Immunotherapy of advanced pancreatic carcinoma with the monoclonal antibody BW 494].
Identifieur interne : 005B23 ( Main/Exploration ); précédent : 005B22; suivant : 005B24[Immunotherapy of advanced pancreatic carcinoma with the monoclonal antibody BW 494].
Auteurs : RBID : pubmed:3349938English descriptors
- KwdEn :
- Aged, Antibodies, Monoclonal (adverse effects), Antibodies, Monoclonal (therapeutic use), Antibodies, Neoplasm (analysis), Antibody-Dependent Cell Cytotoxicity, Carcinoma (immunology), Carcinoma (radionuclide imaging), Carcinoma (therapy), Dose-Response Relationship, Immunologic, Drug Evaluation, Female, Humans, Indium Radioisotopes (diagnostic use), Male, Middle Aged, Pancreatic Ducts, Pancreatic Neoplasms (immunology), Pancreatic Neoplasms (radionuclide imaging), Pancreatic Neoplasms (therapy), Pregnancy, Time Factors.
- MESH :
- chemical , adverse effects : Antibodies, Monoclonal.
- chemical , analysis : Antibodies, Neoplasm.
- chemical , diagnostic use : Indium Radioisotopes.
- chemical , therapeutic use : Antibodies, Monoclonal.
- immunology : Carcinoma, Pancreatic Neoplasms.
- radionuclide imaging : Carcinoma, Pancreatic Neoplasms.
- therapy : Carcinoma, Pancreatic Neoplasms.
- Aged, Antibody-Dependent Cell Cytotoxicity, Dose-Response Relationship, Immunologic, Drug Evaluation, Female, Humans, Male, Middle Aged, Pancreatic Ducts, Pregnancy, Time Factors.
Abstract
In the course of a phase I study monoclonal antibody BW 494 was injected i.v. at a dose of 180-340 mg to 18 patients with advanced ductal pancreatic carcinoma. The murine IgG1-antibody is directed against a pancreatic carcinoma-associated glycoprotein. The antibody inhibits the functions of human pancreatic carcinoma cells. Diffuse muscle pain, which disappeared spontaneously, was noted by two patients 14 days after injection. Other side-effects were anaphylactoid reactions in two patients 12 and 19 days, respectively, on repeat antibody infusions. This event led to changes in the administration schema so that the total amount was given within ten days, after which there were no further allergic side-effects. Terminal antibody half-life was 47.8 h (initial half-life 0.2 h). Human anti-mouse antibodies in all eight patients tested for them developed within two to three weeks of the end of treatment. There were no tumour remissions. Progression of the tumour after treatment occurred in 12 patients (67%). In five patients the course was stable for at least three months after treatment, i.e. unchanged clinical status, unchanged tumour extent (CT), and stable tumour markers (CEA, CA 19-9) in serum. One female patient with a T3N1M0 carcinoma has so far lived for 16 months in full employment. The results justify the use of the monoclonal antibody in future controlled trials.
DOI: 10.1055/s-2008-1067647
PubMed: 3349938
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Immunotherapy of advanced pancreatic carcinoma with the monoclonal antibody BW 494].</title><author><name sortKey="B Chler, M" uniqKey="B Chler M">M Büchler</name><affiliation wicri:level="4"><nlm:affiliation>Abteilung für Allgemeine Chirurgie, Universität Ulm.</nlm:affiliation><country>Allemagne</country><placeName><settlement type="city">Ulm</settlement><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Tübingen</region></placeName><orgName type="university">Université d'Ulm</orgName></affiliation></author><author><name sortKey="K Bel, R" uniqKey="K Bel R">R Kübel</name></author><author><name sortKey="Malfertheiner, P" uniqKey="Malfertheiner P">P Malfertheiner</name></author><author><name sortKey="Friess, H" uniqKey="Friess H">H Friess</name></author><author><name sortKey="Schulz, G" uniqKey="Schulz G">G Schulz</name></author><author><name sortKey="Bosslet, K" uniqKey="Bosslet K">K Bosslet</name></author><author><name sortKey="Beger, H G" uniqKey="Beger H">H G Beger</name></author></titleStmt><publicationStmt><date when="1988">1988</date><idno type="RBID">pubmed:3349938</idno><idno type="pmid">3349938</idno><idno type="doi">10.1055/s-2008-1067647</idno><idno type="wicri:Area/Main/Corpus">006110</idno><idno type="wicri:Area/Main/Curation">006110</idno><idno type="wicri:Area/Main/Exploration">005B23</idno></publicationStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Antibodies, Monoclonal (adverse effects)</term><term>Antibodies, Monoclonal (therapeutic use)</term><term>Antibodies, Neoplasm (analysis)</term><term>Antibody-Dependent Cell Cytotoxicity</term><term>Carcinoma (immunology)</term><term>Carcinoma (radionuclide imaging)</term><term>Carcinoma (therapy)</term><term>Dose-Response Relationship, Immunologic</term><term>Drug Evaluation</term><term>Female</term><term>Humans</term><term>Indium Radioisotopes (diagnostic use)</term><term>Male</term><term>Middle Aged</term><term>Pancreatic Ducts</term><term>Pancreatic Neoplasms (immunology)</term><term>Pancreatic Neoplasms (radionuclide imaging)</term><term>Pancreatic Neoplasms (therapy)</term><term>Pregnancy</term><term>Time Factors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antibodies, Monoclonal</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Antibodies, Neoplasm</term></keywords><keywords scheme="MESH" type="chemical" qualifier="diagnostic use" xml:lang="en"><term>Indium Radioisotopes</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Monoclonal</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Carcinoma</term><term>Pancreatic Neoplasms</term></keywords><keywords scheme="MESH" qualifier="radionuclide imaging" xml:lang="en"><term>Carcinoma</term><term>Pancreatic Neoplasms</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Carcinoma</term><term>Pancreatic Neoplasms</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Antibody-Dependent Cell Cytotoxicity</term><term>Dose-Response Relationship, Immunologic</term><term>Drug Evaluation</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Pancreatic Ducts</term><term>Pregnancy</term><term>Time Factors</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In the course of a phase I study monoclonal antibody BW 494 was injected i.v. at a dose of 180-340 mg to 18 patients with advanced ductal pancreatic carcinoma. The murine IgG1-antibody is directed against a pancreatic carcinoma-associated glycoprotein. The antibody inhibits the functions of human pancreatic carcinoma cells. Diffuse muscle pain, which disappeared spontaneously, was noted by two patients 14 days after injection. Other side-effects were anaphylactoid reactions in two patients 12 and 19 days, respectively, on repeat antibody infusions. This event led to changes in the administration schema so that the total amount was given within ten days, after which there were no further allergic side-effects. Terminal antibody half-life was 47.8 h (initial half-life 0.2 h). Human anti-mouse antibodies in all eight patients tested for them developed within two to three weeks of the end of treatment. There were no tumour remissions. Progression of the tumour after treatment occurred in 12 patients (67%). In five patients the course was stable for at least three months after treatment, i.e. unchanged clinical status, unchanged tumour extent (CT), and stable tumour markers (CEA, CA 19-9) in serum. One female patient with a T3N1M0 carcinoma has so far lived for 16 months in full employment. The results justify the use of the monoclonal antibody in future controlled trials.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">3349938</PMID><DateCreated><Year>1988</Year><Month>04</Month><Day>22</Day></DateCreated><DateCompleted><Year>1988</Year><Month>04</Month><Day>22</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0012-0472</ISSN><JournalIssue CitedMedium="Print"><Volume>113</Volume><Issue>10</Issue><PubDate><Year>1988</Year><Month>Mar</Month><Day>11</Day></PubDate></JournalIssue><Title>Deutsche medizinische Wochenschrift (1946)</Title><ISOAbbreviation>Dtsch. Med. Wochenschr.</ISOAbbreviation></Journal><ArticleTitle>[Immunotherapy of advanced pancreatic carcinoma with the monoclonal antibody BW 494].</ArticleTitle><Pagination><MedlinePgn>374-80</MedlinePgn></Pagination><Abstract><AbstractText>In the course of a phase I study monoclonal antibody BW 494 was injected i.v. at a dose of 180-340 mg to 18 patients with advanced ductal pancreatic carcinoma. The murine IgG1-antibody is directed against a pancreatic carcinoma-associated glycoprotein. The antibody inhibits the functions of human pancreatic carcinoma cells. Diffuse muscle pain, which disappeared spontaneously, was noted by two patients 14 days after injection. Other side-effects were anaphylactoid reactions in two patients 12 and 19 days, respectively, on repeat antibody infusions. This event led to changes in the administration schema so that the total amount was given within ten days, after which there were no further allergic side-effects. Terminal antibody half-life was 47.8 h (initial half-life 0.2 h). Human anti-mouse antibodies in all eight patients tested for them developed within two to three weeks of the end of treatment. There were no tumour remissions. Progression of the tumour after treatment occurred in 12 patients (67%). In five patients the course was stable for at least three months after treatment, i.e. unchanged clinical status, unchanged tumour extent (CT), and stable tumour markers (CEA, CA 19-9) in serum. One female patient with a T3N1M0 carcinoma has so far lived for 16 months in full employment. The results justify the use of the monoclonal antibody in future controlled trials.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Büchler</LastName><ForeName>M</ForeName><Initials>M</Initials><Affiliation>Abteilung für Allgemeine Chirurgie, Universität Ulm.</Affiliation></Author><Author ValidYN="Y"><LastName>Kübel</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Malfertheiner</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Friess</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Schulz</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Bosslet</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Beger</LastName><ForeName>H G</ForeName><Initials>HG</Initials></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType>English Abstract</PublicationType><PublicationType>Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Immuntherapie des fortgeschrittenen Pankreaskarzinoms mit dem monoklonalen Antikörper BW 494.</VernacularTitle></Article><MedlineJournalInfo><Country>GERMANY, WEST</Country><MedlineTA>Dtsch Med Wochenschr</MedlineTA><NlmUniqueID>0006723</NlmUniqueID><ISSNLinking>0012-0472</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Antibodies, Neoplasm</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Indium Radioisotopes</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName MajorTopicYN="N">adverse effects</QualifierName><QualifierName MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Antibodies, Neoplasm</DescriptorName><QualifierName MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Antibody-Dependent Cell Cytotoxicity</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Carcinoma</DescriptorName><QualifierName MajorTopicYN="N">immunology</QualifierName><QualifierName MajorTopicYN="N">radionuclide imaging</QualifierName><QualifierName MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Dose-Response Relationship, Immunologic</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Drug Evaluation</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Indium Radioisotopes</DescriptorName><QualifierName MajorTopicYN="N">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y">Pancreatic Ducts</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Pancreatic Neoplasms</DescriptorName><QualifierName MajorTopicYN="N">immunology</QualifierName><QualifierName MajorTopicYN="N">radionuclide imaging</QualifierName><QualifierName MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1988</Year><Month>3</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1988</Year><Month>3</Month><Day>11</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1988</Year><Month>3</Month><Day>11</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">3349938</ArticleId><ArticleId IdType="doi">10.1055/s-2008-1067647</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005B23 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 005B23 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= IndiumV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:3349938
|texte= [Immunotherapy of advanced pancreatic carcinoma with the monoclonal antibody BW 494].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:3349938" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a IndiumV2
| This area was generated with Dilib version V0.5.76. |  |